-- Newron Declines 12% in Zurich Trading as Talks Over Sale to Santhera End
-- B y   P h i l   S e r a f i n o
-- 2011-02-03T08:05:53Z
-- http://www.bloomberg.com/news/2011-02-03/newron-declines-12-in-zurich-trading-as-talks-over-sale-to-santhera-end.html
  Newron Pharmaceuticals SpA , the
Italian drugmaker developing a Parkinsonâ€™s disease treatment
with Merck KGaA, fell in Zurich trading after saying talks with
Santhera Pharmaceuticals Holding AG have ended.  The stock fell 80 centimes, or 12 percent, to 5.90 Swiss
francs at 9:05 a.m.  To contact the editor responsible for this story:
Phil Serafino at 
 pserafino@bloomberg.net  